Article citationsMore>>

Hameed, S., Wasay, M., Soomro, B.A., Mansour, O., Abd-Allah, F., Tu, T., Farhat, R., Shahbaz, N., Hashim, H., Alamgir, W. and Iqbal, A. (2021) Cerebral Venous Thrombosis Associated with COVID-19 Infection: An Observational, Multicenter Study. Cerebrovascular Diseases Extra, 11, 55-60.
https://doi.org/10.1159/000516641

has been cited by the following article:

• TITLE: Prevalence of Cerebral Venous Thrombosis in COVID-19 Patients: A Systematic Review

  AUTHORS: Ohood A. Ashahrani, Musa S. Alfaifi

  KEYWORDS: Prevalence, CVT, COVID-19

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.6, June 8, 2022

  ABSTRACT: Background: COVID-19 is a novel coronavirus that has been rapidly transmitted between individuals globally. COVID-19 has been associated with thrombotic events. A cerebral venous thrombosis is a rare form of stroke with a most common site of origin believed to be the junction of larger sinuses and cerebral veins. So, it is important to identify the prevalence and incidence of cerebral venous thrombosis among COVID-19 patients. Aim: To assess the prevalence of cerebral venous thrombosis in COVID-19 patients by reviewing the previous studies reported on this subject. Method: We searched for articles focused on our subject through PubMed and Google scholar databases. The included searching terms included “CVT, COVID-19, Prevalence, Complications, and Effect.” The inclusion criteria were studies conducted on COVID-19 patients, English articles, available full-text articles, and original articles. Result: We got 1178 articles; only six articles were eligible for the inclusion criteria. The included articles involved a total number of 551,727 participants with a mean age ranging between 34 years and 53.3 years and covered seven countries. The incidence of CVT among COVID-19 was reported as well as risk factors and symptoms. Conclusion: The incidence of CVT is high among COVID-19 patients compared to the general population, patients with influenza, and those who received the mRNA vaccine, whereas the prevalence requires further studies for precise data. A management strategy or treatment regimen should be established based on the severity of CVT patients, as the mortality rate among those patients was high.